Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
The FDA approved a high‑dose formulation of Biogen’s SMA drug Spinraza, cutting the loading phase from four to two injections and adding a four‑month maintenance schedule. The new regimen, backed by the DEVOTE study, showed significant motor‑skill gains versus sham and a safety profile comparable to the original dose. Biogen hopes the approval will halt the recent sales slide—down to under $1.55 billion in 2025—and serve as a bridge to its next‑generation antisense candidate, salanersen. Analysts view the move as a strategic effort to stabilize the SMA franchise amid rising competition.
AstraZeneca is testing its COPD triple‑inhaler Breztri Aerosphere in uncontrolled asthma. Phase III KALOS and LOGOS trials showed 76‑90 mL improvements in FEV₁ and a 14% reduction in severe exacerbations versus standard ICS/LABA therapy. The studies enrolled about 4,300 patients across 20...
Red and near‑infrared light therapy, known as photobiomodulation, has shifted from clinics to the consumer health market, prompting a surge in device sales and investor interest. In the United States, products reach consumers via distinct FDA pathways: 510(k) clearance for...
An international team of more than 40 scientists released the human E3‑ome, a curated atlas that consolidates 672 high‑confidence E3 ligases from over 1,100 candidates. The resource offers a gold‑standard reference for basic research and drug discovery, addressing long‑standing inconsistencies...
Scientists at Manchester University have identified a recessive RNU2‑2‑related neurodevelopmental disorder as one of the most common genetic causes of childhood epilepsy. The condition, which manifests with seizures and severe delays in speech and walking before age one, has been...
The New England Journal of Medicine released the CREST‑2 results, a pair of parallel randomized trials that compared intensive medical management (IMM) alone with IMM plus either carotid stenting (TFCAS) or carotid endarterectomy (CEA) in patients with asymptomatic high‑grade carotid...
The module introduces HitID screens, outlining key strategies for early-stage drug discovery. It references recent literature on medicinal chemistry optimization, successful hit‑to‑clinical transitions, DNA‑encoded library (DEL) approaches, ultra‑low‑molecular‑weight crystallographic screening, and fragment‑based drug discovery (FBDD). By consolidating these sources, the...
New Jersey remains a heavyweight pharma cluster, home to giants like Johnson & Johnson and Merck, while nurturing a growing biotech startup scene. Companies such as ArrePath, BioAegis, Celularity, Enalare, EpiBone, Inaedis and Rocket Pharmaceuticals are advancing AI‑driven antibiotics, plasma‑protein...
Zongertinib (Hernexeos) received FDA accelerated approval for first‑line treatment of HER2‑mutant advanced NSCLC, based on Beamion LUNG‑1 data presented at the European Lung Cancer Congress. In previously untreated patients (cohort 2), the drug achieved a 76% objective response rate and a...
As a medical school professor, I taught that aging was caused by DNA mutations accumulating over time. A landmark study from my friend Dave Sinclair's team in Cell just overturned that entire framework. The researchers created mice that age faster --...
1/🚨@TesseraTx has announced that it has received a grant from the Gates Foundation to fund an early-stage research which is aimed to develop a Gene Editing-based cure for HIV. This grant is build upon Tessera’s existing investment 🧵👇 from the Gates...
UK Biotech Day 2026 will take place on May 27‑28 at the Radisson Hotel & Conference Centre London Heathrow. The two‑day conference convenes executives, R&D scientists, investors, legal and finance professionals from pharma, biotech, medtech, and tech‑bio sectors. Positioned as...
Senescent endothelial cells: key commanders of the cellular communication network within atherosclerotic plaques https://t.co/yzyxR0KPAL https://t.co/RBqSrKkvks
At a March 25 reception marking the first anniversary of the National Security Commission on Emerging Biotechnology report, BIO President John F. Crowley warned that China’s rapid biotech expansion threatens U.S. health security. The commission’s findings cite a 400‑fold rise...
The U.S. FDA has approved a higher‑dose version of Biogen’s gene‑replacement therapy for a rare genetic muscle‑weakening disorder, likely spinal muscular atrophy. The new regimen starts with two 50 mg loading doses two weeks apart, followed by a 28 mg maintenance dose...
A comprehensive 2026 meta‑analysis of 113 clinical trials and nearly 8,000 participants concludes that hydrolysed collagen supplements produce moderate improvements in muscle health, lessen osteoarthritis pain, and enhance skin elasticity and hydration. The findings revive scientific and consumer interest in...
Researchers analyzing more than 15,000 human fat samples have identified the SLIT3 protein as a potent enhancer of brown‑fat calorie burning. The discovery suggests a novel, metabolism‑focused avenue for obesity treatment and biohacking beyond appetite‑suppressing drugs.
GLP‑1 weight‑loss drugs are generating buzz as potential appetite suppressants, but current adoption remains modest—about 12% of U.S. adults and even lower in Europe. While the drugs can mute the so‑called “food noise” and trim a few percentage points off...
A Chinese biotech company administered the first-in-human dose of a hepatitis D‑targeted monoclonal antibody in Beijing, marking a world‑first for the disease. The trial details were not disclosed, and it comes as the broader pharma sector grapples with earnings pressure,...
Researchers at The Jackson Laboratory and MIT unveiled a polymer‑based microneedle skin patch that captures immune cells and inflammatory biomarkers within 15‑30 minutes. The device could transform vaccine response tracking and chronic disease monitoring by eliminating the need for blood...
AstraZeneca announced that its experimental monoclonal antibody tozorakimab met primary endpoints in two late‑stage COPD trials, delivering a clinically meaningful reduction in moderate‑to‑severe flare‑ups. The data lifted the company’s shares as much as 3.8% and underpin a sales outlook of...
Eli Lilly and Hong Kong‑listed Insilico Medicine have sealed a partnership that could be worth up to $2.75 billion, including a $115 million upfront payment. The deal gives Lilly exclusive global rights to Insilico’s pre‑clinical oral candidates and taps the biotech’s generative‑AI platform....
Researchers at South Korea's KAIST have demonstrated that graphene oxide can selectively eradicate bacterial cells while leaving human cells intact. The finding points to a new class of nanomaterial‑based antibiotics that could help combat the growing threat of antimicrobial resistance.
Bioventix Plc announced first‑half earnings that fell 4% year‑over‑year to £3.62 million, with earnings per share slipping to £0.6845. Revenue contracted 8.6% to £6.15 million, highlighting mounting headwinds for the UK biotech sector amid tighter investor scrutiny and pending regulatory decisions.
Researchers at Washington University School of Medicine and Children’s Hospital of Philadelphia have demonstrated that volatile organic compounds (VOCs) in exhaled breath mirror gut microbiome activity. Published in Cell Metabolism, the proof‑of‑concept study showed breath profiles could differentiate children with...
Researchers at the University of York have identified ESB2, an RNA endonuclease that acts as a molecular shredder within Trypanosoma brucei. By selectively degrading transcripts, ESB2 fine‑tunes Variant Surface Glycoprotein expression, allowing the parasite to evade host immunity. The finding,...
Eli Lilly is urging the United Kingdom to overhaul its drug‑pricing framework, warning that persistently low prices could deter future investment and calling for outcomes‑based reimbursement models, especially for obesity therapies. At the same time, the U.S. Food and Drug Administration...
On Jan. 20, 2025 President Donald Trump signed an executive order that recognizes only two sexes and mandates federal agencies use the term “sex” instead of “gender.” The order abruptly removed the NIH Sex as a Biological Variable (SABV) policy webpages, unsettling...
Researchers at Sun Yat‑sen University's National Key Laboratory of Ophthalmology published a PNAS paper revealing that the protein MTFR1L maintains mitochondrial homeostasis in the heart and can slow age‑related cardiac decline. The findings open a molecular pathway for biohackers and...
Boston Scientific announced that its EKOS™ Endovascular System, combined with anticoagulation, lowered the 7‑day composite endpoint for intermediate‑risk pulmonary embolism to 4.0% versus 10.3% with anticoagulation alone, a 61% relative reduction. The findings, presented at ACC.26 and published in NEJM,...
Scientists have demonstrated magnetic nanorobots smaller than blood cells that can be steered by external magnets to deliver chemotherapy directly to tumors. The technology aims to cut side effects and enable new hyperthermia treatments, signaling a potential shift in nanomedicine.
Wall Street analysts project that GLP-1 focused biotech stocks could see their valuations triple before the end of 2026. The forecast highlights market leaders Novo Nordisk and Eli Lilly, while also flagging Viking Therapeutics as a high‑risk, high‑reward play.
Sleep disturbances and Alzheimer’s disease: a multiscale approach from exposome to neurobiology and precision medicine "a hypothetical integrative, stream-like model outlining how external and internal exposome factors accelerate brain aging, thereby exacerbating circadian dysregulation, orexin-mediated hyperexcitability, metabolic imbalance, and inflammaging." https://t.co/VJPZRqmM23
Johns Hopkins Medicine and Unbound Medicine have published the first ever clinical guidance on psychedelic medicine through the Johns Hopkins Psychiatry POC‑IT Guide. The guidance targets clinicians treating treatment‑resistant depression and PTSD, offering evidence‑based recommendations as psychedelic‑assisted therapies near FDA...
A research team led by KAIST has identified how graphene oxide (GO) can selectively attack bacterial membranes while sparing mammalian cells, demonstrating rapid wound‑healing in mouse and pig models. The discovery could accelerate antimicrobial product development without relying on traditional...
Kailera Therapeutics, one of biotech’s best‑funded startups, announced plans to go public to finance the Phase 3 trial of its obesity drug co‑developed with China’s Hengrui. The IPO aims to raise capital that will position the company against heavyweight rivals such...
CK Life Sciences, the Li Ka‑shing‑backed unit, has created Sequencio Therapeutics in Hong Kong to fast‑track its cancer‑vaccine pipeline in mainland China using investigator‑initiated trials (IITs). The fast‑track channel can cut trial start‑up time from 18‑24 months to a few months,...
The SPIRIT‑HF trial, designed to test spironolactone in heart‑failure patients with preserved or mildly reduced ejection fraction, enrolled only 730 of the planned 1,564 participants and therefore lacked statistical power. Over two years, the composite of cardiovascular death or total...
Small molecules that alter RNA structure, rather than simply binding to it, have a greater impact on RNA function, highlighting the importance of targeting RNA folding in drug development. molecularbiology
Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study https://t.co/YUcSc7w9HG
Rocket Pharmaceuticals received FDA approval on March 27 for KRESLADI, its first marketed product and the first gene therapy for a rare pediatric disorder. The clearance also awarded the company a Rare Pediatric Disease Priority Review Voucher, which can be...
Allogene Therapeutics announced that its lead CAR‑T candidate cemacabtagene ansegedleucel (cema‑cel) stays on track in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation in large B‑cell lymphoma, enrolling over 60 sites globally. An interim futility analysis is slated for April 2026...
Allogene Therapeutics announced that its lead CAR‑T candidate cema‑cel remains on schedule in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation of large B‑cell lymphoma, now enrolling at more than 60 sites worldwide. An interim futility analysis is set for...
Aardvark Therapeutics announced on March 23, 2026 that it is voluntarily pausing its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome and the ARD‑201 obesity program while it consults the FDA. The decision follows cardiac findings in healthy‑volunteer studies, where...
Researchers at UT Southwestern reported encouraging early results from a deep brain stimulation (DBS) trial targeting treatment‑resistant depression, a condition affecting roughly 30% of patients who fail conventional therapies. The study, part of the national TRANSCEND trial, suggests that electrical...
A Cleveland Clinic secondary analysis of a 13,000‑patient trial shows tirzepatide lowers the combined risk of heart attack, stroke, heart failure, kidney failure and death by 16% versus dulaglutide. The findings, presented at the ACC meeting, give longevity‑focused biohackers new...
Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review https://t.co/LGgQeHQHwF https://t.co/OiCYu2OxZq
Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice 👉"Our results are consistent with the idea that rapamycin’s beneficial effects are mediated, at least in part, by reducing oxidative stress and ER stress-mediated apoptosis... https://t.co/b8EZwrDTXP
